Case report links naloxone reversal to tachycardia in a dog

A case report newly published as a preprint and described for publication in Animals highlights an uncommon but clinically relevant recovery event: marked sinus tachycardia after naloxone administration in a dog recovering from anesthesia. The patient, a 7-year-old male neutered Labrador retriever undergoing comprehensive oral health assessment and treatment, had a documented history of ventricular premature contractions, making the episode especially notable for anesthesia teams managing higher-risk cardiac patients. (preprints.org)

The case builds on a longer clinical history. Nine months before the dental procedure, the dog had presented for acute facial swelling and was sedated with dexmedetomidine and fentanyl, at which time ventricular premature contractions were confirmed. A later cardiology consultation reportedly found no obvious structural abnormality, but the arrhythmic history remained relevant. During the dental anesthetic itself, VPCs were again observed when norepinephrine was administered, reinforcing the possibility that this dog had an exaggerated cardiovascular response to sympathetic or anesthetic perturbation. (preprints.org)

According to the report, the dog received acepromazine and hydromorphone premedication, midazolam and propofol induction, and a fentanyl CRI that ran for about four hours. Recovery was prolonged, and naloxone was administered 75 minutes after the fentanyl infusion had been stopped. The authors argue that, based on published fentanyl pharmacokinetics in dogs, major drug accumulation would not necessarily be expected at that point, which is part of what makes the tachycardic response noteworthy. They propose that naloxone may have triggered a rapid rise in plasma catecholamines, producing the observed sinus tachycardia. (preprints.org)

That interpretation fits with broader anesthesia guidance, even if direct veterinary evidence remains limited. Educational guidance for veterinary anesthesia notes that complete opioid antagonism can precipitate acute pain and sympathetic stimulation, with downstream effects including tachycardia and arrhythmias. Separate work in dogs has also shown that naloxone exposure can alter fentanyl pharmacokinetic behavior, with one recent MDPI paper reporting correlations between naloxone exposure and delayed re-sedation after fentanyl reversal in dogs. Taken together, those data don’t prove causation in this case, but they support the authors’ concern that opioid reversal can have more complex cardiovascular and recovery effects than a simple “on-off” model suggests. (dvm360.com)

There’s also relevant context around the rest of the anesthetic protocol. Dexmedetomidine product labeling in dogs lists both tachycardia and VPCs among observed adverse events, and published anesthesia references emphasize that tachycardia during anesthesia or recovery can reflect multiple competing causes, including inadequate analgesia, light anesthetic plane, hypoxia, hemorrhage, or drug effects. In other words, naloxone may have been the proximate trigger here, but clinicians still need to think broadly when interpreting recovery tachycardia. (dailymed.nlm.nih.gov)

Why it matters: For veterinary professionals, the case is less about proving a new adverse effect than about sharpening risk awareness in recovery. Dogs with known ventricular ectopy, prior arrhythmic events, or heavy opioid exposure may deserve especially deliberate reversal plans, close ECG surveillance, and a clear rationale for full versus partial antagonism. The report also underscores a practical point: prolonged recovery after fentanyl doesn’t automatically mean reversal will be benign, and abrupt opioid antagonism may trade one problem for another in select patients. That’s particularly relevant in referral, emergency, dentistry, and specialty anesthesia settings where multimodal protocols and vasoactive support are common. (preprints.org)

Published case literature adds nuance here. Naloxone has been used successfully in dogs to reverse suspected fentanyl-induced muscle rigidity during ventilator weaning, with uneventful extubation afterward. That contrast is useful: the same antagonist can be clearly beneficial in one recovery complication and destabilizing in another, depending on patient factors, timing, dose, and the underlying problem being treated. (doaj.org)

What to watch: Watch for the final peer-reviewed Animals publication, any follow-up correspondence from veterinary anesthesiologists, and whether this case influences discussion around titrated naloxone dosing, partial reversal strategies, or monitoring recommendations for dogs with preexisting arrhythmic histories. (preprints.org)